ReviewCurrent biology : CB2025
Cryptococcus.
Review in Current biology : CB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations.Microorganisms · 2026Review
- A poly(trisulfide) oligomer with antimicrobial activity.Chemical science · 2026Article
- Cryptococcus neoformans adapts to host CO2 concentrations via metabolic and stress-response remodeling.PLoS biology · 2026Article
- Use of a human immortalized microglia cell line to study recognition, phagocytosis, and intracellular survival ofmSphere · 2026Article
- Mitochondrial cardiolipin sequestration of caspofungin underliesbioRxiv : the preprint server for biology · 2026Article
- Article
- Breaking down the wall: Solid-state NMR illuminates how fungi build and remodel diverse cell walls.PLoS pathogens · 2025Article
- 1,5-Diarylidene-4-Piperidones as Promising Antifungal Candidates AgainstAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fungal pathogens pose a significant threat to human health that is greatly underrecognized, despite causing several million deaths every year. To put it simply, the fight against these fungi is complicated. At baseline, there is a severe lack of effective and accessible antifungals, especially in regions with limited resources. Exacerbating the situation, many of these pathogens are opportunists that primarily affect immunocompromised individuals, which adds to the challenges of treatment. Another concern is that climate change selects for thermotolerance in environmental fungi, enhancing their ability to thrive at human body temperatures. This may not only intensify the danger of existing pathogens but also lead to the emergence of new ones. To focus attention on the serious and escalating threat of fungal pathogens, the World Health Organization has recently classified them into priority categories, designating Cryptococcus neoformans as "critical priority". In this primer, we will discuss the fundamental biology that makes C. neoformans such a notorious pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.